top of page
In the Media
Our groundbreaking tuberculosis research and community impact featured across international publications.
Fortune Magazine
The Gates Foundation will end in 2045. What will the world look like without it?
Be Part Yoluntu Centre featured as one of the key sites in a global clinical trial for a new tuberculosis vaccine, highlighting our role in the Gates Foundation's global health impact.
8 May 2025
Spotlight NSP
High Hopes for Major TB Vaccine Study Recently Launched in Paarl
Local coverage of the promising tuberculosis vaccine research taking place in our community, highlighting the potential breakthrough in TB prevention.
26 March 2025
Gates Foundation
A Trusted Voice in the Fight Against TB
Spotlight on Nandipha Titana and Be Part Yoluntu Centre's community-centered approach to tuberculosis prevention and treatment, featuring our holistic healthcare model.
24 March 2025
Social Media Recognition
Featured in a LinkedIn post by Mark Suzman, CEO of the Gates Foundation, showcasing our global health networks and professionals.
March 2025
IAVI
First Vaccinations in IMAGINE Clinical Trial for TB Vaccine MTBVAC
Historic milestone achieved as the first participants in the groundbreaking IMAGINE trial were vaccinated at Be Part Yoluntu Centre in Paarl, marking a crucial step in TB vaccine development.
26 February 2025
"It's not just an injection of IV, it's also an injection of dignity."
- Dr. Ronald Kapp, Be Part Yoluntu Centre
bottom of page